This website contains information intended exclusively for physicians, pharmacists, and other qualified healthcare professionals.

Please confirm your status to continue

By clicking “Yes,” you confirm that you are a licensed healthcare professional and acknowledge that this content is intended for professional use only and not intended for use by the general public.

{"id":5736,"date":"2024-02-25T15:18:55","date_gmt":"2024-02-25T15:18:55","guid":{"rendered":"https:\/\/diagnosticgreen.com\/row\/?p=5736"},"modified":"2025-09-25T16:23:48","modified_gmt":"2025-09-25T15:23:48","slug":"new-indication-approved-for-verdye-indocyanine-green-for-injection-icg-for-breast-sentinel-lymph-node-mapping","status":"publish","type":"post","link":"https:\/\/diagnosticgreen.com\/row\/events\/new-indication-approved-for-verdye-indocyanine-green-for-injection-icg-for-breast-sentinel-lymph-node-mapping\/","title":{"rendered":"New Indication Approved for Verdye (Indocyanine Green for Injection, ICG) for Breast Sentinel Lymph Node Mapping"},"content":{"rendered":"\n
\n\n\n\n

Date:<\/strong>\u00a0February 05, 2024
Location:<\/strong>\u00a0Athlone, Ireland<\/p>\n\n\n\n

Diagnostic Green Plc (Diagnostic Green) is pleased to announce the approval of Verdye (ICG) for intraoperative identification of sentinel lymph nodes and visualisation pathways in breast cancer in\u00a0Spain.<\/p>\n\n\n\n

The presence of lymphatic metastases is an important prognostic factor for the survival of breast cancer. Sentinel lymph node biopsy (SLNB) continues to be a fundamental component of early breast cancer detection and is the current standard of care to help determine whether cancer has spread to the lymph nodes.<\/p>\n\n\n\n

With the approval of ICG for breast SLNB, surgeons now have an alternative to using Technetium (99mTc) radio-labelled colloids with blue dyes (BD) to visualise lymph nodes. Using 99mTc is a significant burden for both patients as well as hospitals which includes logistical challenges associated with pre-procedure administration, the risk of exposure to ionizing radiation for professionals and all the requirements associated with radiopharmaceutical handling. Additionally, blue dyes can pose significant potential risks including soft tissue necrosis, metabolic and hematologic side effects, making it infrequently utilised for routine surgical care.<\/p>\n\n\n\n

In discussing the approval, Declan Cassells, Managing Director of Diagnostic Green stated that, “This is a great advancement for breast SLN detection, leveraging the real-time imaging capabilities ICG. The intraoperative use of ICG not only matches or surpasses the accuracy of current approaches but also notably improves the patient experience, offering a safer and less invasive alternative to traditional methods involving Technetium and blue dyes for SLN detection.”<\/p>\n\n\n\n

The approval was supported by multiple meta-analyses studies which concluded that<\/p>\n\n\n\n